



Please type a plus sign (+) inside this box → **+**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified) PTO/SB/21 (6-98)  
Approved for use through 09/30/2000. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1632

# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	09/340,283
Filing Date	June 25, 1999
First Named Inventor	Messing, Robert O.
Group Art Unit	1632
Examiner Name	R. Shukla
Attorney Docket Number	316-000720US

Total Number of Pages in This Submission

7

## ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Preliminary Amendment	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below):
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Terminal Disclaimer	receipt acknowledgment postcard
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Request for Refund	

### Authorization to Charge Deposit Account

Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.

Remarks

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Emily M. Haliday, Reg. No. 38,903, Quine Intellectual Property Law Group P.C.		
Signature	<i>Emily M. Haliday</i>		
Date	Mar. 27, 2002		

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: 3-27-02

Typed or printed name	Tracie Brooks		
Signature	<i>Tracie Brooks</i>	Date	3-27-02

I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington, D.C. 20231, on

March 27, 2002  
LAW OFFICES OF JONATHAN ALAN QUINE

By:

*Francis Bwala*

#240  
Dai  
4/24/02  
Atty Docket No: 316-000720US  
Client Ref: GALO-007/10US



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Robert O. Messing; Clyde W. Hodge

Application No.: 09/340,283

Filed: 6/25/1999

For: **PROTEIN KINASE C EPSILON AS  
A MODULATOR OF ANXIETY,  
ALCOHOL CONSUMPTION, AND SELF-  
ADMINISTRATION OF DRUGS OF  
ABUSE**

Examiner: Shukla, R.

Art Unit: 1632

**RECEIVED**  
APR 15 2002  
TECH CENTER 1600/2900

**PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

This paper supplements the continued prosecution application filed on March 12, 2002. Applicants respectfully request reconsideration of the above-identified application in view of the following amendments and remarks.

Please amend the specification and/or claims as follows:

**In the Claims:**

Please cancel pending claims 10, 29, 31-33, 35-39, 54, and 55 without prejudice.

Please enter the following claims:

56. A method of screening for an agent that modulates anxiety, said method comprising:
- a) exposing a PKCε to a test agent;
  - b) detecting binding of the test agent to the PKCε, wherein the ability to bind PKCε indicates that the test agent is a potential modulator of anxiety.

NO  
SUB E